- Home
- ATHA vs SNSE Comparison
ATHA vs SNSE Comparison
Compare ATHA & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- SNSE
- Stock Information
- Founded
- ATHA 2011
- SNSE 2005
- Country
- ATHA United States
- SNSE United States
- Employees
- ATHA N/A
- SNSE N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- SNSE Health Care
- Exchange
- ATHA Nasdaq
- SNSE Nasdaq
- Market Cap
- ATHA 10.6M
- SNSE 10.8M
- IPO Year
- ATHA 2020
- SNSE 2021
- Fundamental
- Price
- ATHA $0.42
- SNSE $8.17
- Analyst Decision
- ATHA Buy
- SNSE Strong Buy
- Analyst Count
- ATHA 4
- SNSE 3
- Target Price
- ATHA $11.25
- SNSE $86.67
- AVG Volume (30 Days)
- ATHA 239.8K
- SNSE 12.9K
- Earning Date
- ATHA 07-31-2025
- SNSE 08-05-2025
- Dividend Yield
- ATHA N/A
- SNSE N/A
- EPS Growth
- ATHA N/A
- SNSE N/A
- EPS
- ATHA N/A
- SNSE N/A
- Revenue
- ATHA N/A
- SNSE N/A
- Revenue This Year
- ATHA N/A
- SNSE N/A
- Revenue Next Year
- ATHA N/A
- SNSE N/A
- P/E Ratio
- ATHA N/A
- SNSE N/A
- Revenue Growth
- ATHA N/A
- SNSE N/A
- 52 Week Low
- ATHA $0.22
- SNSE $5.00
- 52 Week High
- ATHA $3.67
- SNSE $17.40
- Technical
- Relative Strength Index (RSI)
- ATHA 73.73
- SNSE 50.67
- Support Level
- ATHA $0.29
- SNSE $8.76
- Resistance Level
- ATHA $0.32
- SNSE $9.27
- Average True Range (ATR)
- ATHA 0.03
- SNSE 0.52
- MACD
- ATHA 0.01
- SNSE -0.00
- Stochastic Oscillator
- ATHA 78.16
- SNSE 42.84
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).